Ph.D., President & Chief Scientific Officer, Caris Life Sciences
Biography
Dr. Spetzler joined Caris Life Sciences® in August of 2009, and has held several manage¬ment positions with increasing responsibilities during his tenure. He currently serves as President and Chief Scientific Officer and provides executive leadership for the com¬pany’s service lines, Caris Molecular Intelligence® and ADAPT Biotargeting System®. Under his leadership, the R&D team is focused on the development of clinical assays to aid in the creation of precision medicine strategies for individual cancer patients, as well as noninvasive technologies to identify and predict early stage cancer. Much of work is focused on the development of the ADAPT Biotargeting System®, a groundbreaking and proprietary method of profiling macro-molecular complexes in their native form in a highly multiplexed format. The innovative technology is the result of the convergence of Caris’ deep expertise in Next-Generation Sequencing, exosome biology, bioinformatics and broad-based molecular profiling.
Genomic Profiling:
Caris Life Sciences
Caris Life Sciences is an innovative biotechnology company, actively working to fulfill the promise of precision medicine through our unique and transformative platforms to help patients with cancer and other complex diseases.
Application Of Next Generation Profiling (NGP) To Molecular Data Sets
Caris NGP, powered by our advanced machine learning platform, DEAN, helps define complex biomarkers that can improve patient outcomes. NGP identifies unique molecular signatures by cancer subtypes, predicts which patients might respond to specific treatments, and improves cancer diagnosis.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 11.15 A.M.-1.15 P.M.,Track 7 - January 24 2.30 P.M.-3.45 P.M.
The PMWC 2020 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
